CD274 and neoplasm: Unfortunately, for patients with metastatic castration-resistant prostate cancer (mCRPC), the objective response rate to ICI treatments is reported to be around 3% for those without programmed cell death ligand 1 (PD-L1) expression and 5% for those with PD-L1-expressing tumours [33].